Invention Grant
- Patent Title: ALX receptor ligands define a biochemical endotype for inflammation-based diseases
-
Application No.: US16482216Application Date: 2018-01-25
-
Publication No.: US11519911B2Publication Date: 2022-12-06
- Inventor: Bruce Levy , Charles N. Serhan
- Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
- Applicant Address: US MA Boston
- Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
- Current Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
- Current Assignee Address: US MA Boston
- Agency: Haukaas Fortius PLLC
- Agent Colin L. Fairman
- International Application: PCT/US2018/015287 WO 20180125
- International Announcement: WO2018/144316 WO 20180809
- Main IPC: G01N33/566
- IPC: G01N33/566
Abstract:
A method to determine the severity of a disease of chronic inflammation in a patient, comprising the steps of (1) collection or preparation of a bodily fluid, tissue or lavage and (2) measurement of ALX receptor ligands or ALX receptor expression in the fluid, tissue, or lavage, wherein the level of ALX receptor ligands predicts a clinical outcome or choice of treatment modality, is disclosed.
Public/Granted literature
- US20190391145A1 ALX RECEPTOR LIGANDS DEFINE A BIOCHEMICAL ENDOTYPE FOR INFLAMMATION-BASED DISEASES Public/Granted day:2019-12-26
Information query
IPC分类:
